Key facts
- This page summarizes Marc Bregman's Form 4 filing for ELITE PHARMACEUTICALS INC /NV/ (ELTP).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 07 Jul 2021, 17:00.
Marc Bregman - 17 May 2021 Form 4 Insider Report for ELITE PHARMACEUTICALS INC /NV/ (ELTP)
- Reporting relationship
- CFO, Secretary, Treasurer
- Issuer ticker
- ELTP
- Reported as of
- 17 May 2021
- Net transaction value
- +$16,860
- Reporting owner signature
- Marc Bregman
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
Marc Bregman filed Form 4 for ELITE PHARMACEUTICALS INC /NV/ (ELTP) on 07 Jul 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: +$16,860.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ELTP
transaction
Derivative
Options
Award
- Transaction value
- $16,860
- Shares
- +300,000
- Change %
- Price
- $0.0562
- Shares after
- 300,000
- Date
- 17 May 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 300,000
- Exercise price
- $0.0562
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Options were awarded by the Board of Directors as part of Mr. Bregman's employment agreement.
Footnote F2
The options will vest over a three-year period, commencing one year from the date of issuance. The first third will vest on May 17, 2022